Modus Therapeutics Holding AB (publ) (STO:MODTX)

STO:MODTX Balance Sheet

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	16.53	4.38	19.06	10.42	20.65	7.35
Cash & Short-Term Investments	16.53	4.38	19.06	10.42	20.65	7.35
Cash Growth	38.12%	-77.03%	82.85%	-49.52%	181.12%	433.79%
Other Receivables	0.87	0.19	0.67	0.23	0.25	0.14
Receivables	0.87	0.19	0.67	0.23	0.25	0.14
Prepaid Expenses	-	0.26	0.26	0.57	0.24	0.01
Total Current Assets	17.41	4.83	19.99	11.22	21.14	7.49
Other Long-Term Assets	0.05	0.05	0.05	0.05	0.05	-
Total Assets	17.46	4.88	20.04	11.27	21.19	7.49
Accounts Payable	1.75	1.56	1.31	1.36	4.49	0.11
Accrued Expenses	0.93	0.96	0.53	0.86	0.83	0.31
Short-Term Debt	-	-	-	11.5	-	-
Current Income Taxes Payable	-	-	-	0.04	-	0.03
Other Current Liabilities	0.23	0.23	0.52	0.1	0.14	0.05
Total Current Liabilities	2.91	2.75	2.36	13.86	5.46	0.5
Other Long-Term Liabilities	-	-	-	-	-0	-
Total Liabilities	2.91	2.75	2.36	13.86	5.46	0.5
Common Stock	7.3	2.16	2.16	0.97	0.97	0.04
Additional Paid-In Capital	353.39	332.9	332.9	295.93	295.93	257.23
Retained Earnings	-346.14	-332.92	-317.37	-299.48	-281.16	-250.28
Comprehensive Income & Other	-	0	-	-	0	-
Shareholders' Equity	14.55	2.14	17.68	-2.59	15.74	7
Total Liabilities & Equity	17.46	4.88	20.04	11.27	21.19	7.49
Total Debt	-	-	-	11.5	-	-
Net Cash (Debt)	16.53	4.38	19.06	-1.08	20.65	7.35
Net Cash Growth	38.12%	-77.03%	-	-	181.12%	-
Net Cash Per Share	0.40	0.12	1.07	-0.07	1.67	1.24
Filing Date Shares Outstanding	121.63	35.94	35.94	16.1	16.1	8.6
Total Common Shares Outstanding	121.63	35.94	35.94	16.1	16.1	8.6
Working Capital	14.5	2.09	17.63	-2.64	15.68	7
Book Value Per Share	0.12	0.06	0.49	-0.16	0.98	0.81
Tangible Book Value	14.55	2.14	17.68	-2.59	15.74	7
Tangible Book Value Per Share	0.12	0.06	0.49	-0.16	0.98	0.81

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.